Patents
Elekta aims to provide the highest level of cancer treatment possible, which means combining the most advanced technology with the most effective treatment techniques. In addition to working with industry and academic leaders through collaborative sponsored research programs, Elekta has its own extensive research and development program, which has resulted in a patent portfolio covering many important innovations in cancer care.
依照第287条(a)的标题35 the United States Code, and Section 15 of the UK’s Intellectual Property Act 2014, the reader is hereby placed on notice of Elekta's intellectual property rights for the following products protected by granted patents in the United States and the United Kingdom.
Agility™
Beam Modulator™
Clarity®
- US 7,535,411
- US 7,634,304
- US 7,662,097
- US 7,672,705
- 我们7729744
- US 8,000,442
- US 8,135,198
- US 8,189,738
- US 8,199,981
- US 8,249,317
- US 8,929,621
- US 9,248,316
- US 9,451,928
- EP 1,304,960 B1
- EP 1,774,312 B1
- EP 1,778,351 B1
- EP 1,778,074 B1
- EP 1,871,232 B1
- EP 1,913,333 B1
- EP 2,036,037 B1
- EP 2,063,960 B1
- EP 2,175,931 B1
- EP 2,293,843 B1
Connexion™
Elekta Axesse™
Elekta Infinity™
Elekta Synergy®
Extend™
- EP 2,186,489 B1
- EP 2,112,457 B1
- US 8,393,821 B2
- US 8,100,132 B2
- US 8,088,083 B2
iViewGT™
Leksell Coordinate Frame G
- US 8,221,435 B2,
- EP 1,503,689 B1
Leksell Gamma Knife® Icon™
- US 6,931,096 B2
- US 7,313,222 B2
- US 6,968,036 B2
- US 7,492,866 B2
- US 7,729,473 B2
- EP 1,540,668 B1
- EP 1,540,667 B1
- EP 1,761,307 B1
- EP 1,868,684 B1
- EP 2,326,390 B1
Leksell Gamma Knife® Perfexion™
- US 6,931,096 B2,
- US 7,313,222 B2,
- US 6,968,036 B2,
- US 7,492,866 B2,
- EP 1,540,668 B1,
- EP 1,540,667 B1,
- EP 1,761,307 B1,
- EP 1,868,684 B1,
Leksell GammaPlan®
- EP 2,069,016 B1
Leksell® Vantage™ Stereotactic System
Monaco®
- US 6,249,594
- US 6,266,453
- US 6,512,942
- US 7,171,255
- US 7,187,800
- US 7,201,715
- US 7,438,645
- US 8,098,909
- US 8,265,356
- US 8,577,107
- US 8,731,258
- US 8,867,806
- US 9,122,950
- US 9,122,959
- US 9,367,958
- US 9,460,360
- US 9,539,441
- US 9,572,998
- US 9,656,099
- US 9,764,162
- US 9,256,965
- 我们9629 598
- US 9,697,602
- US 9,740,710
- US 9,764,162
- US 9,652,871
- US 9,878,177
- US 9,974,977
- US 9,947,102
- 我们9965863
Symmetry™
Versa HD™
XVI
XVI 5.0.1
Patent licensing
Elekta aims to provide the highest level of cancer treatment possible, which means combining the most advanced technology with the most effective treatment techniques. In addition to working with industry and academic leaders through research programmes, Elekta also acquires mature technology which has been proven to increase treatment accuracy, enhance the patient experience or improve treatment outcomes.
Elekta understands the importance of intellectual property and the role it plays in encouraging innovation and entrepreneurialism, having an extensive patent portfolio which covers many of the most important innovations in cancer care of the last four decades. However, we are always seeking new opportunities to augment our product range and intellectual property portfolio.
If you have a patented or patent pending cancer treatment technology or system that you think Elekta might be interested in, we want to hear from you. Please send your inquiry along with any additional information and contact details by completing the form below: